NVAXNovavax, Inc.

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$682M+22.6% YoY

Gross Profit

$479M70.3% margin

Operating Income

-$249M-36.5% margin

Net Income

-$187M-27.5% margin

EPS (Diluted)

$-1.23

Cash Flow

Operating Cash Flow

-$87M

Free Cash Flow

-$100M

Stock-Based Comp.

$48M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$2.2B

Stockholders' Equity

-$624M

Cash & Equivalents

$530M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$682M	$556M	+22.6%
Gross Profit	$479M	$213M	+125.5%
Operating Income	-$249M	-$567M	+56.1%
Net Income	-$187M	-$545M	+65.6%

NVAX FY 2024 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena